These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20945984)

  • 21. [Proteomic biomarkers in Parkinson's disease].
    Bandrés S; Durán R; Barrero F; Ramírez M; Vives F
    Rev Neurol; 2014 Feb; 58(4):166-74. PubMed ID: 24504879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease.
    Visanji NP; Mollenhauer B; Beach TG; Adler CH; Coffey CS; Kopil CM; Dave KD; Foroud T; Chahine L; Jennings D;
    Biomark Med; 2017 Apr; 11(4):359-368. PubMed ID: 28353371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The significance of oxidized DJ-1 protein (oxDJ-1) as a biomarker for Parkinson's disease].
    Ogawa I; Saito Y; Saigoh K; Hosoi Y; Mitsui Y; Noguchi N; Kusunoki S
    Brain Nerve; 2014 Apr; 66(4):471-7. PubMed ID: 24748095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The DJ-1 concentration in cerebrospinal fluid does not differentiate among Parkinsonian syndromes.
    Salvesen L; Bech S; Lokkegaard A; Hjermind LE; Nielsen JE; Pakkenberg B; Tanassi JT; Heegaard NH; Winge K
    Parkinsonism Relat Disord; 2012 Aug; 18(7):899-901. PubMed ID: 22503539
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical genetics of Parkinson's disease and related disorders.
    Wider C; Wszolek ZK
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S229-32. PubMed ID: 18267241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secretion of DJ-1 into the serum of patients with Parkinson's disease.
    Maita C; Tsuji S; Yabe I; Hamada S; Ogata A; Maita H; Iguchi-Ariga SM; Sasaki H; Ariga H
    Neurosci Lett; 2008 Jan; 431(1):86-9. PubMed ID: 18162323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of preanalytical conditions on the DJ-1 concentration in human cerebrospinal fluid.
    Salvesen L; Tanassi JT; Bech S; Pålhagen S; Svenningsson P; Heegaard NH; Winge K
    Biomark Med; 2014; 8(3):387-94. PubMed ID: 24712430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of the DJ-1 protein in the serum of Chinese patients with Parkinson's disease.
    An C; Pu X; Xiao W; Zhang H
    Neurosci Lett; 2018 Feb; 665():236-239. PubMed ID: 29241707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of recent genetic findings in Parkinson's disease.
    Klein C; Lohmann-Hedrich K
    Curr Opin Neurol; 2007 Aug; 20(4):453-64. PubMed ID: 17620882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of genetic analysis on Parkinson's disease research.
    Hardy J
    Mov Disord; 2003 Sep; 18 Suppl 6():S96-8. PubMed ID: 14502662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Genetics and present therapy options in Parkinson's disease: a review].
    Bereznai B; Molnar MJ
    Ideggyogy Sz; 2009 May; 62(5-6):155-63. PubMed ID: 19579663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mitochondrial dysfunction and oxidative damages in the molecular pathology of Parkinson's disease].
    Shadrina MI; Slominskiĭ PA
    Mol Biol (Mosk); 2008; 42(5):809-19. PubMed ID: 18988530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.
    del Campo M; Mollenhauer B; Bertolotto A; Engelborghs S; Hampel H; Simonsen AH; Kapaki E; Kruse N; Le Bastard N; Lehmann S; Molinuevo JL; Parnetti L; Perret-Liaudet A; Sáez-Valero J; Saka E; Urbani A; Vanmechelen E; Verbeek M; Visser PJ; Teunissen C
    Biomark Med; 2012 Aug; 6(4):419-30. PubMed ID: 22917144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetics of Parkinson's disease: what do mutations in DJ-1 tell us?
    Moore DJ; Dawson VL; Dawson TM
    Ann Neurol; 2003 Sep; 54(3):281-2. PubMed ID: 12953259
    [No Abstract]   [Full Text] [Related]  

  • 36. [Parkinson's disease: what have we learned from the genes responsible for familial forms?].
    Corti O; Brice A
    Med Sci (Paris); 2003 May; 19(5):613-9. PubMed ID: 12836396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.
    Merchant KM; Cedarbaum JM; Brundin P; Dave KD; Eberling J; Espay AJ; Hutten SJ; Javidnia M; Luthman J; Maetzler W; Menalled L; Reimer AN; Stoessl AJ; Weiner DM;
    J Parkinsons Dis; 2019; 9(1):31-61. PubMed ID: 30400107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The biochemistry of Parkinson's disease.
    Cookson MR
    Annu Rev Biochem; 2005; 74():29-52. PubMed ID: 15952880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers in Parkinson's disease: an update.
    Shtilbans A; Henchcliffe C
    Curr Opin Neurol; 2012 Aug; 25(4):460-5. PubMed ID: 22772875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of α-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease?
    Mollenhauer B
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S76-9. PubMed ID: 24262194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.